GSK loses Seretide patent
The High Court has upheld a claim by Cipla and other generic firms that a key patent on Seretide, also known as Advair, which expires in 2013, is invalid on the grounds of obviousness. The High Court said that the claimants’ case was ‘overwhelmingly strong’
. The case rested on whether GSK scientists had taken a truly inventive step when combining two older drugs, Flovent and Serevent, to make Seretide/Advair. The Court said that the combination was ‘entirely obvious’
. GSK conceded that the relevant patent was not as strong in the UK as it was in the US.
The rest of this document is only available to i-law.com online subscribers.
If you are already a subscriber, please enter your details below to log in.
If you are not already a subscriber, please select one of the options below.
Sign up for a free trial or for further assistance call your Account Manager or our
Customer support: +44 (0)20 7017 7701 Technical Support: +44 (0) 20 7017 4161